Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Core Insights - Rakovina Therapeutics is set to present new data at the Society for Neuro-Oncology Annual Meeting, focusing on AI-driven cancer therapies targeting DNA-damage response inhibitors for brain cancers [1][2]. Presentation Details - The company will showcase two posters on November 21, 2025, detailing the discovery and development of CNS-penetrating ATR and PARP1-selective inhibitors [3][4]. - The first poster discusses the kt-5000AI ATR inhibitor program, developed with Variational AI, highlighting the discovery of potent ATR inhibitors effective against treatment-resistant tumors [3]. - The second poster covers the kt-2000AI PARP inhibitor program, utilizing the Deep Docking™ platform for virtual screening of billions of compounds to identify CNS-penetrant inhibitors [4]. Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [7][8]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [8].